Biohaven Ltd.
For the period ended Mar 31, 2026. Filed May 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities
Maskbegone Agreement
In January 2026, we entered into the Maskbegone Agreement with Maskbegone, pursuant to which we obtained the exclusive rights to develop and commercialize certain products developed under the Maskbegone Agreement related to the use of oxytocin and derivatives of oxytocin in the treatment of tinnitus. As partial consideration under the Maskbegone Agreement, we were obligated to pay an upfront payment of 76,383 common shares valued at approximately $0.9 million, which were issued in the first quarter of 2026.
The foregoing issuance and sale of our common shares in connection with the execution of the Maskbegone Agreement have not been registered under the Securities Act or any state securities laws. We have relied on the exemption from the registration requirements of the Securities Act under Section 4(a)(2) thereof, for a transaction by an issuer not involving any public offering.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.